In the present study we aimed to establish the frequency with which patients frequenting our institution visit and leave comments on IPRS, identify those sites most commonly visited, and evaluate the nature of comments written.
We compared setting preference at baseline and at a 6-week follow-up visit and evaluated the preferred male partner testing settings among participants randomized to either clinic-based or home-based testing.
Every six to eight weeks, or at shorter intervals if necessary, the RN will visit the participant and evaluate the CTP.
For patients discharged to a nursing home or rehabilitation centre, the same steps will be conducted but the CN visit the patients in these settings and contacts the Nursing Home Physician (NHP) for consultation After 2, 6, 12 and 24 weeks, the CN visits the patients and evaluates the care- and treatment plan, the impact and the (intended) results.
That year, the A.M.A. commissioned a well-known educator, Abraham Flexner, to visit and evaluate each North American medical school.
The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2393/13/68/prepub The author thanks Dr. Alice Zelmanowicz for her assistance in the elaboration of this study, the Medical Cooperative for granting permission to carry out the study and evaluating the office visits, and to UFRGS for providing the knowledge for research development.
The study protocol required the pediatricians to hospitalize infants who show more than ten percent weight decrease between visits and to evaluate the need for hospitalizing infants with ten percent or less weight decrease based on the infant's health, medical complications and standard pediatric judgment.
The frequency and severity of all reported adverse events will be recorded at every visit to evaluate the safety and tolerability of treatment with lanreotide.
Patients completed at least three visits in order to be evaluated (one for initial prescription of the single drug, one for evaluating the headache outcome with the initial chosen drug, when the inclusion of the second drug was carried out and a third visit to evaluate the outcomes with the two drugs).
The mMRC will be observed and recorded at every visit to evaluate the symptom of dyspnoea.
